Lake Street Capital Upgrades Kyntra Bio (NASDAQ:KYNB) to Strong-Buy

Kyntra Bio (NASDAQ:KYNB) was upgraded by Lake Street Capital to a “strong-buy” rating in a research report issued on Thursday, Zacks reports.

KYNB has been the topic of a number of other research reports. Oppenheimer initiated coverage on shares of Kyntra Bio in a report on Monday, July 6th. They set an “outperform” rating and a $35.00 price target on the stock. Rodman & Renshaw started coverage on shares of Kyntra Bio in a research report on Tuesday, June 9th. They set a “buy” rating and a $30.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $43.00 price target on shares of Kyntra Bio in a research report on Tuesday, September 1st. Finally, Weiss Ratings upgraded Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.

Kyntra Bio Price Performance

Shares of Kyntra Bio stock opened at $7.10 on Thursday. The firm has a market cap of $28.75 million, a price-to-earnings ratio of 0.16 and a beta of 1.06. The stock has a 50-day simple moving average of $7.46 and a 200-day simple moving average of $7.18. Kyntra Bio has a 52-week low of $6.32 and a 52-week high of $12.58.

Institutional Trading of Kyntra Bio

A hedge fund recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC bought a new stake in Kyntra Bio Inc (NASDAQ:KYNB) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio as of its most recent SEC filing. Institutional investors own 72.71% of the company’s stock.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.